Quick Answer
Ascendis Pharma A/S reported R&D Expense of $303.62 million for fiscal year 2025.
Ascendis Pharma A/S R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $303.62M | -1.1% |
| 2024 | $307.00M | -25.7% |
| 2023 | $413.45M | +8.9% |
| 2022 | $379.62M | +28.3% |
| 2021 | $295.87M | +13.4% |
| 2020 | $260.90M | +36.2% |
| 2019 | $191.62M | +36.6% |
| 2018 | $140.28M | +40.9% |
| 2017 | $99.59M | +50.8% |
| 2016 | $66.02M | +62.9% |
| 2015 | $40.53M | — |
- Ascendis Pharma A/S showed a decrease of -1.1% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, Ascendis Pharma A/S’s r&d expense has grown by 649.2% (from $40.53 million to $303.62 million).
- The most recent figure is from Ascendis Pharma A/S’s fiscal year 2025 report (Form 20-F), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: